Breaking News Instant updates and real-time market news.

TMO

Thermo Fisher

$151.19

0.41 (0.27%)

09:49
10/18/16
10/18
09:49
10/18/16
09:49

Thermo Fisher demand trends remain soft, says Cleveland Research

Cleveland Research said recent work continues to indicate demand trends over the past few months remain soft as European government, U.S. academic, and global pharma companies have incrementally slowed their growth in R&D spending. Consequently, the firm continues to expect 3Q16 organic growth of 3% for Thermo Fisher but believes the company needs to raise FY16 guidance by 7c-9c to reflect FEI accretion. Cleveland rates Thermo Fisher a Neutral.

  • 26

    Oct

  • 27

    Oct

TMO Thermo Fisher
$151.19

0.41 (0.27%)

08/18/16
CANT
08/18/16
NO CHANGE
Target $165
CANT
Speculative Buy
Thermo Fisher unlikely to acquire Illumina, says Cantor
Cantor Fitzgerald analyst Bryan Brokmeier believes it is unlikely that Thermo Fisher (TMO) will attempt to acquire Illumina (ILMN). Even if Thermo were to attempt a deal, the merger would be unlikely to close, Brokmeier tells investors in an intraday research note. If Illumina is a willing seller, however, Roche (RHHBY) may reconsider a bid, the analyst contends. He recommends investors stay on the sidelines with respect to Illumina shares. Brokmeier has a Hold rating on the name with a $165 price target. The analyst continues to believe Roche is the most likely acquirer of Pacific Biosciences (PACB).
08/24/16
CLVD
08/24/16
NO CHANGE
CLVD
Thermo Fisher, VWR Q3 estimates trimmed at Cleveland Research
Cleveland Research analyst Steve Willoughby's research suggests the Life Science Industry has gotten off to a slow start in Q3 due to a modest deceleration among pharma customers, European softness following Brexit, and concerns over a slowdown in US government funding. The analyst trimmed estimates on Thermo Fisher (TMO) and VWR (VWR) pending further research.
09/09/16
CLVD
09/09/16
DOWNGRADE
CLVD
Neutral
Thermo Fisher downgraded to Neutral from Buy at Cleveland Research
Cleveland Research analyst Steve Willoughby downgraded Thermo Fisher to Neutral following checks that indicate softer trends. The firm's feedback points to concerns over the remainder of the year and the polity change in China that could impact year-end equipment sales in the country.
09/22/16
JPMS
09/22/16
INITIATION
Target $180
JPMS
Overweight
Thermo Fisher reinstated with Overweight, added to Focus List at JPMorgan
JPMorgan analyst Tycho Peterson reinstated Thermo Fisher Scientific with an Overweight rating and raised his price target for the shares to $180 from $160. The rating is unchanged from the firm's prior coverage. Peterson added Thermo to his firm's Analyst Focus List as a value pick.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.